FDA Clears Quidel Influenza A+B Assay

San Diego-based developer of diagnostic testing solutions Quidel received FDA clearance for its QuickVue Influenza A+B assay.

The assay allows for the rapid, qualitative detection of influenza type A and type B antigens directly in nasal swab and nasopharyngeal swab specimens, the company said.

It is designed to identify and differentiate between the two influenza viruses in about 10 minutes.